Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | PRKACA | P17612 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879319 | 0.88 | CDK4 (0.49) | PDGFRBPDGFRAFLT1KDREGFR | |
| SCHEMBL5879259 | 0.82 | KDM4E (0.44) | PDGFRBCAMK2DPIM1PRKACAHTR1A | |
| SCHEMBL5879170 | 0.82 | F7 (0.45) | CAMK2DGPR84PIM1PRKACAHTR1A | |
| SCHEMBL5879151 | 0.82 | BRAF (0.44) | PDGFRBKDRKITCAMK2DPIM1 | |
| SCHEMBL5879255 | 0.82 | IGF1R (0.50) | PDGFRBPDGFRAFLT1KDRIGF1R | |
| SCHEMBL5879171 | 0.82 | CLK1 (0.45) | PDGFRBPDGFRAFLT1KDREGFR | |
| SCHEMBL7826604 | 0.81 | KDR (0.68) | PDGFRBPDGFRAFLT1KDREGFR | |
| SCHEMBL5879148 | 0.79 | KDR (0.57) | PDGFRBKDRCAMK2DGPR84HTR1A | |
| SCHEMBL10433674 | 0.79 | JAK2 (0.46) | PDGFRBPDGFRAFLT1KDREGFR | |
| SCHEMBL10433665 | 0.79 | IDO1 (0.46) | CAMK2DCDK5CDK5R1PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218206-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-110526903-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2021-12-10 | — | — | CN | disclosed |
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | PDGFRB 678/4885PDGFRA 801/4885FLT1 1256/4885 |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | PDGFRB 3313/4885PDGFRA 3211/4885FLT1 2339/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | PDGFRB 549/4885PDGFRA 679/4885FLT1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.